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Purpose: This study aimed to evaluate the correlation between associating factors 
of moderate to severe asthma with obstructive sleep apnea (OSA). Materials and 
Methods: One hundred and sixty-seven patients who visited the pulmonary and 
sleep clinic in Severance Hospital presenting with symptoms of sleep-disordered 
breathing were evaluated. All subjects were screened with ApneaLink. Thirty-two 
subjects with a high likelihood of having OSA were assessed with full polysom-
nography (PSG). Results: The mean age was 58.8±12.0 years and 58.7% of sub-
jects were male. The mean ApneaLink apnea-hypopnea index (AHI) was 
12.7±13.0/hr. The mean ApneaLink AHI for the 32 selected high risk patients of 
OSA was 22.3±13.2/hr, which was lower than the sleep laboratory-based PSG 
AHI of 39.1±20.5/hr. When OSA was defined at an ApneaLink AHI ≥5/hr, the 
positive correlating factors for OSA were age, male gender, and moderate to se-
vere asthma. Conclusion: Moderate to severe asthma showed strong correlation 
with OSA when defined at an ApneaLink AHI ≥5/hr.
Key Words:   Apnea-hypopnea index, ApneaLink, asthma, obstructive sleep ap-
nea, sleep-disordered breathing
INTRODUCTION
Obstructive sleep apnea syndrome (OSA) is characterized by repeated episodes of 
upper airway obstruction that results in brief periods of breathing cessation (apnea) 
or a marked reduction in airflow (hypopnea) during sleep. OSA is the most severe 
form of obstructive sleep-disordered breathing (SDB). OSA is a common disorder 
with a prevalence estimated at 10-20%.1,2 Risk factors for OSA include male gender, 
age, obesity, and nocturnal nasal congestion.2 A population-based study in Korea re-
ported the prevalence of OSA was 4.5% and 3.2% in men and women, respectively.3
Previous epidemiologic studies demonstrated that patients with asthma have an 
increased risk of OSA.4-6 In an Australian longitudinal study, asthma was an inde-
pendent risk factor for the development of habitual snoring.7 A prospective cohort 
study showed a high prevalence of OSA in patients with difficult-to-control asth-
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Severe asthma required at least one of the following ma-
jor criteria: daily oral steroid use for >50% of the previous 
12 months or a high-dose inhaled steroid (≥1000 mg/day 
fluticasone or equivalent) and at least one additional contin-
uous add-on therapy for ≥12 months. Severe asthma also 
required at least two of the following minor criteria: use of 
a daily short-acting β-agonist, a persistent forced expiratory 
volume in one second (FEV1) <70%, a predicted forced vi-
tal capacity (FEV1/FVC) of <80%, at least one urgent visit 
or at least three steroid bursts in the last 12 months, prompt 
deterioration with <25% steroid dose reduction, or a previ-
ous near-fatal asthma attack within the last three years. 
Moderate asthma was defined as well-controlled asthma 
symptoms, the use of a long-acting β-agonist at ≥200 mg/
day and fluticasone (or an equivalent) at ≤1000 mg/day, at 
least two steroid bursts in the past year and none within the 
last three months, <30 total days on oral steroids within the 
last 12 months, a predicted FEV1 of >70%, and at least one 
unscheduled clinical visit within the previous 12 months. 
Asthma was defined as a positive response to 1) being diag-
nosed with asthma, 2) having wheezed in the last 12 months, 
3) taking corticosteroids and objective evidence of variable 
airway obstruction, following the diagnostic criteria of  Glob-
al Initiative for Asthma (GINA) guidelines. Additionally a 
demonstration of a positive bronchodilator test (increase in 
FEV1 ≥12% and 200 mL) or a positive methacholine chal-
lenge test within the previous year was required.
Pregnant women and patients with significant cognitive 
impairment, a poorly controlled psychiatric disorder, or who 
had previous treatment for OSA were excluded.   
All subjects provided informed consent to join the study. 
The Institutional Review Board of the Clinical Research In-
stitute of Severance Hospital, Yonsei University College of 
Medicine, approved the study protocol (IRB number: 4- 
2011-0448).
Design
This was a cross-sectional study. Patients presented with 
symptoms of SDB were enrolled. All subjects agreed to use 
the ApneaLink device at home for one night after being in-
structed on the use of the device by an experienced sleep 
technician. Subjects returned the ApneaLink device to the 
pulmonary and sleep clinic the following morning, and the 
data were downloaded and analyzed. Patients with a high 
likelihood of having OSA were assessed with full PSG with-
in 2 weeks after the ApneaLink study. We investigated all 
established diagnoses of lung and other comorbidities at en-
ma.8 On the contrary, OSA may aggravate asthma because 
treatment for OSA has been shown to improve asthma symp-
toms.9 The National Asthma Education and Prevention Pro-
gram Expert Panel Report recommends OSA evaluation be-
cause it is a potential contributor to poor asthma control.10 
For such reasons, a more specific understanding of what in-
creases a predisposition for OSA would be useful. 
It has been suggested that gastroesophageal reflux disease 
(GERD), postnasal drip syndrome, and obesity may contrib-
ute to the development of OSA, but the role of each of these 
conditions in OSA has not been studied.11,12 To date, many 
studies have investigated the risk or prevalence of OSA in 
asthma patients; however, there is lack of data concerning 
the prevalence of asthma in high-risk OSA patients. There-
fore, we investigated the predisposing factors of moderate to 
severe asthma in high OSA risk patients and assessed possi-
ble associations to predict other risk factors for OSA.
Although sleep laboratory-based polysomnography (PSG) 
is currently regarded as the gold standard for the diagnosis 
of sleep apnea,13 it is labor-intensive, costly, and has limited 
availability.14 The use of a portable recording device such 
as the ApneaLink for screening sleep apnea has some po-
tential advantages in terms of cost, convenience, and better 
sleep quality for patients.15 Portable recording devices may 
be used as an alternative to PSG for the diagnosis of OSA 
in patients with a high pretest probability of moderate to se-
vere OSA.16 Recently, two studies validated the use of Ap-
neaLink for the screening of sleep apnea compared with 
PSG.17,18 As such, we used ApneaLink for OSA screening 
to estimate the predisposing factors of moderate to severe 
asthma in high OSA risk patients and to assess possible as-




All subjects were adults age ≥18 years that visited the pulmo-
nary and sleep clinic at Severance hospital from February 
2007 to August 2008 with symptoms of daytime sleepiness, 
choking and gasping during sleep, recurrent awakenings 
from sleep, unrefreshed sleep, daytime fatigue, and impaired 
concentration.13,19 
The enrolled patients were checked for diagnoses of lung 
and other comorbidities. Patients diagnosed with asthma 
were categorized by severity according to the American 
Thoracic Society criteria20 and difficult asthma study.21 
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10 seconds or a discernible decrease leading to an at least 
3% oxygen desaturation or an EEG arousal. 
Statistical analysis
Data was analyzed using SPSS for windows, version 18.0 
(SPSS Inc., Chicago, IL, USA). A Bland-Altman plot is a 
graphic representation of the observed differences between 
paired measurements. The differences between ApneaLink 
and PSG were plotted against the averages of the two meth-
ods. Results showing a mean difference close to zero indi-
cate little systemic bias. Correlation analysis was carried 
out using Pearson correlation coefficients. The p-values of 
<0.05 were considered statistically significant. Multivariate 
logistic regression analysis was used to predict independent 
risk factors for OSA (age, gender, asthma, diabetes, cardio-
vascular disease, habitual snoring, and obesity) that demon-
strated statistically significant univariate relationships. We 
defined mild OSA as 15>AHI≥5/hr, and moderate OSA as 
30>AHI≥15/hr, and severe OSA as AHI≥30/hr, according 





One hundred and sixty-seven subjects who visited the pul-
monary and sleep clinics as well as complained of habitual 
snoring, OSA, and excessive daytime sleepiness completed 
the ApneaLink study. Of the 167 patients, 32 (19.2%) pa-
tients with a high likelihood of having OSA were assessed 
with full PSG within 2 weeks after the ApneaLink study. 
Thirty-two who patients performed PSG were selected by 
physician’s decision according to definite symptoms of 
OSA without objective criteria. The characteristics of the 
rollment, such as bronchial asthma, chronic obstructive pul-
monary disease (COPD), GERD, rhinitis, diabetes, cardio-
vascular disease, and habitual snoring. Past smoking and 
body mass index (BMI) were also identified. In patients 
with asthma, current and previous asthma medications were 
recorded and recent spirometry data was collected to assess 
asthma severity.
Device
The ApneaLinkTM device (ResMed, Sydney, Australia) is a 
portable single-channel screening tool for sleep apnea. The 
device consists of a nasal cannula attached to a small case 
that houses a pressure transducer. The ApneaLink software 
analyzes data generated by the flow signal, producing a re-
port that provides information regarding snoring and inspi-
ratory flow limitation; only the apnea-hypopnea index 
(AHI) information was used for this study. The ApneaLink 
default settings for apnea and hypopnea were used in this 
study. Apnea was defined as a decrease in airflow by 80% 
of baseline for at least 10 seconds and hypopnea was de-
fined as a decrease in airflow by 50% to 80% of baseline 
for at least 10 seconds. The ApneaLink AHI was automati-
cally analyzed by the ApneaLink software version 6.0. 
The overnight in-lab diagnostic PSG (Comet-PLUS® XL, 
Grass Technologies, Warwick, RI, USA) included a record-
ing electro-encephalogram (EEG), electrooculogram, sub-
mental electromyogram (EMG), bilateral anterior tibialis 
EMG, electrocardiogram, chest and abdominal wall move-
ment by inductance plethysmography, and airflow mea-
sured by a nasal pressure transducer. The equipment was 
supplemented with an oral thermistor and finger pulse ox-
imeter.19,22 PSG scoring was performed according to inter-
nationally agreed criteria.13 Apnea was defined as a cessa-
tion of nasal flow lasting 10 seconds or longer. Hypopnea 
was defined as a 50% decrease in nasal flow lasting at least 
Table 1. Demographics and Characteristics of ApneaLink Screened 167 Patients
Characteristics Total
ApneaLink screened patients (n=167)
AHI ≥5/hr AHI <5/hr p value
n (%) 167 (100) 111 (66.5) 56 (33.5) -
Age, yrs (mean±SD)   58.8±12.0 60.1±9.9   56.0±14.9   0.070
Men, n (%) 98 (58.7)   80 (72.1) 18 (32.1) <0.001
BMI, kg/m2 (mean±SD) 25.3±3.8 25.5±4.1 24.8±3.3   0.311
Smoking
    Current of past smokers, n (%) 80 (47.9)   67 (60.4) 13 (23.2) <0.001
    Pack-yrs (mean±SD)   32.4±18.2   33.4±17.8   26.7±19.5   0.231
Habitual snoring, n (%) 91 (54.5)   63 (56.8) 28 (50.0)   0.408
AHI, apnea-hypopnea index; BMI, body mass index; Pack-years, (Packs smoked per day) × (years as a smoker); SD, standard deviation.
Data are presented as the mean±SD and No. (%).
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Associations of comorbidities and clinical parameters 
with OSA
Variables found to be associated with OSA on both univari-
ate and multivariate analyses are shown in Table 3. When 
OSA was defined as AHI ≥5/hr, age, male gender, and mod-
erate to severe asthma showed positive correlations with 
OSA on univariate and multivariate analyses (Table 3). All 
asthma severity groups, including mild asthma did not show 
correlations with OSA. Only moderate to severe asthma 
showed strong correlation with OSA. COPD was not asso-
ciated with OSA, regardless of its severity according to 
FEV1 (data not shown). Diabetes and habitual snoring were 
not found to be predictors. Although cardiovascular disease 
was the most common comorbid condition in this study, it 
was not associated. Postnasal drip syndrome and GERD 
were rare comorbid diseases in our study and consequently 
not showed positive correlations.
DISCUSSION
There are little data showing a correlation between asthma 
and OSA. According to several studies, patients with asth-
167 patients who were screened with the ApneaLink study 
are shown in Table 1. 
The mean age was 58.8±12.0 years and 58.7% were 
male. BMI scores were not different according to the pres-
ence of OSA. Of the 167 patients, 80 patients (47.9%) were 
either current or past smokers. The mean number of pack-
years was 32.4±18.2. Of the current or past smokers, 67 pa-
tients (60.4%) had OSA (AHI ≥5/hr) and 13 patients 
(23.2%) did not. The presence of smoking history showed a 
difference between the OSA and non-OSA groups, but 
there was no difference in pack-years between groups. The 
prevalence of OSA depended on AHI cut-off values; AHI 
values of ≥5/hr, ≥10/hr, ≥15/hr and ≥30/hr corresponded to 
111 (66%), 71 (42.5%), 52 (31%) and 20 (12%) patients, 
respectively. The mean ApneaLink AHI for the 167 
screened patients was 12.7±13.0/hr. The mean ApneaLink 
AHI for the 32 selected high risk patients of OSA was 
22.3±13.2/hr, which was lower than the sleep laboratory-
based PSG AHI of (39.1±20.5/hr). The most common co-
morbidities in decreasing order were cardiovascular disease 
(50.3%), asthma (38.9%), COPD (21%), diabetes (14.4%), 
obesity (10.2%), postnasal drip syndrome (7.8%), and 
GERD (4.8%) (Table 2). 
Table 2. Comorbidities of ApneaLink Screened 167 Patients
Characteristics Total
ApneaLink screened patients (n=167)
AHI ≥5/hr AHI <5/hr p value
Cardiovascular diseases   84 (50.3)   56 (50.5) 28 (50.0) 0.956
Asthma   65 (38.9)   40 (35.1) 25 (41.1) 0.281
    Moderate to severe asthma   44 (26.3)   37 (33.6)   7 (12.5) 0.004
COPD   31 (18.6)   23 (20.7)   8 (14.3) 0.313
    Moderate to severe COPD   17 (10.2)   9 (8.1)   8 (14.3) 0.213
Diabetes   24 (14.4)   17 (15.3)   7 (12.5) 0.624
Obesity (BMI ≥30)   17 (10.2)   12 (10.8) 5 (8.9) 0.704
Postnasal drip syndrome 13 (7.8) 10 (9.0) 3 (5.4) 0.406
GERD   8 (4.8)   6 (5.4) 2 (3.6) 0.600
AHI, apnea-hypopnea index; COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disease; BMI, body mass index.
Data are presented as No. (%). 
Table 3. Univariate and Multivariate Analysis of Affecting Factors for the Presence of OSA (AHI ≥5/hr)
Variables
Unadjusted Adjusted
OR (95% CI) p value OR (95% CI)* p value
Age 1.03 (1.01-1.06) 0.041 1.04 (1.01-1.07) 0.043
Male gender   5.45 (2.71-10.94) <0.001   7.14 (3.21-15.90) <0.001
Moderate to severe asthma 3.22 (1.33-7.83) 0.001   4.25 (1.50-12.16) 0.007
Diabetes 1.27 (0.49-3.26) 0.631 1.80 (0.60-5.56) 0.306
Obesity 1.24 (0.41-3.70) 0.702 1.35 (0.40-4.65) 0.640
Habitual snoring 1.31 (0.69-2.50) 0.408 1.33 (0.63-2.80) 0.455
OR, odds ratio; CI, confidence intervals; OSA, obstructive sleep apnea; AHI, apnea-hypopnea index.  
*Adjusted for all variables shown.
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COPD was not a predicting factor, regardless of severity, 
categorized by FEV1 (data not shown). Cardiovascular dis-
ease was also not associated with OSA, contrary to previ-
ous studies.31,32 We presumed that cardiovascular disease 
has not been well characterized in this study. Moreover, hy-
pertension was the most common condition; not heart fail-
ure, stroke, or coronary heart disease (Table 4). Postnasal 
drip syndrome and GERD were comorbid in very small pa-
tients (9%, 5% respectively) in our study and showed no 
correlations with OSA. Obesity did not show positive cor-
relations with OSA on univariate and multivariate analyses. 
Ip, et al.33 reported that obesity is prevalent and a strong risk 
factor for OSA in white populations but is relatively un-
common in Asians. They hypothesized that other strong 
OSA risk factors, such as craniofacial features, are preva-
lent in Asians, and clinical observational studies of Asian 
patients with OSA support this hypothesis.34-36 In this study, 
the number of obese patients was very small. The preva-
lence of obesity, defined as western cut-off (BMI ≥30 kg/
m2), was only 4.6% in our population.3 Obesity was not 
correlated with OSA in our study and this is similar to a re-
cent study of ethnic differences in craniofacial structures 
and obesity.37
Previous studies have validated ApneaLink as an appro-
priate screening tool for OSA.17,18 Diagnostic accuracy of 
the ApneaLink for OSA detection was evaluated and com-
pared with PSG. The ApneaLink device was highly sensi-
tive and specific in quantifying AHI when compared with 
the AHI obtained from the lab-based PSG. In our study, 32 
patients completed both ApneaLink and PSG studies, and 
ApneaLink AHI and PSG AHI were closely correlated 
(Pearson’s correlation coefficient r=0.613) (Fig. 1). The Ap-
neaLink tended to underestimate the AHI score, which is 
similar to previous studies.17,18 Erman, et al.18 applied Apne-
aLink a screening tool in comparison with the sleep-labora-
tory based PSG. ApneaLink was highly sensitive and spe-
cific in calculating AHI when compared with AHI obtained 
from PSG.18 Ng, et al.17 evaluated the diagnostic accuracy 
of the ApneaLink device in detecting sleep apnea compared 
ma have a higher prevalence of snoring and witnessed ap-
nea relative to patients without asthma,4,23 but the preva-
lence of asthma in patients with OSA was only investigated 
in one small and uncontrolled study.24
We investigated the associating factors thought to increase 
predisposition for OSA, including well-known factors such 
as male gender, age, and obesity and additional possible 
factors including asthma, GERD, postnasal drip syndrome, 
cardiovascular disease, diabetes, smoking, habitual snoring, 
and COPD. Factors with a positive correlation with OSA 
were age, male gender, and moderate to severe asthma 
when OSA was defined at an AHI ≥5/hr. We identified fac-
tors associated with moderate to severe asthma that showed 
positive correlations with OSA. Most patients with moder-
ate to severe asthma had uncontrolled asthma. Irrespective 
of severity, asthma was not an independent predictor of 
OSA. Yigla, et al.8 found that 21 of 22 (96%) patients with 
severe asthma demonstrated OSA in complete PSG testing. 
Julien, et al.25 demonstrated a high prevalence of OSA 
among patients with severe asthma, compared to patients 
with moderate asthma or without asthma. Several plausible 
hypotheses have been proposed to explain the association 
of asthma and OSA including anatomic abnormalities of 
upper air way related to obesity, nasal disease or GERD re-
lated upper airway inflammation, chronic systemic cortico-
steroid use, and airway patency of lung volume reduction 
during sleep in asthmatics.12,26,27 However, these proposed 
mechanisms need to be studied further. The interaction of 
OSA and asthma could be reciprocal in that asthma-related 
factors could also contribute to OSA deterioration. Noctur-
nal hypoxemia could be aggravated by asthma-related lung 
function impairment. Poor sleep quality could also be a fac-
tor because it has been associated with severe asthma in 
previous studies.28,29 In our study, 32 subjects who per-
formed PSG completed the sleep questionnaire of the Ep-
worth Sleepiness Scale (ESS). The ESS mean score was 
over the upper limits of the normal range at 10.38±4.85, 
with approximately 62.5% showing excessive daytime 
sleepiness, defined as an ESS score greater than 10.30  
Table 4. Subgroup Analyses of 84 Patients with Cardiovascular Diseases 
Total AHI ≥5/hr AHI <5/hr p value
Hypertension only 55 37 18 0.511
Coronary artery diseases 15 12   3 0.192
Non-coronary artery diseases 15   8   7 0.198
Heart failure   2   1   1 0.560
AHI, apnea-hypopnea index.
Patients with one more cardiovascular disease are present. Non-coronary artery diseases are arrhythmia, hypertrophic cardiomyopathy and valvular heart 
disease. 
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